论文部分内容阅读
目的验证患者参与管理模式对接受“3C”治疗的T2DM患者血糖控制效果。方法选取泰达国际心血管病医院内分泌科住院的T2DM并接受“3C”治疗的患者125例,随机分为患者参与管理模式组65例和常规模式组60例。结果出院时,患者参与管理模式组FPG[(7.69±1.05)vs(7.13±1.13)mmol/L]、2 hPG[(9.85±1.29)vs(9.10±1.11)mmol/L]、日间血糖平均绝对差(MODD)[(1.90±0.35)vs(1.44±0.25)]、平均血糖波动幅度(MAGE)[(1.36±0.27)vs(1.21±0.21)]与常规模式组比较,差异均有统计学意义(P<0.05)。出院3个月后门诊随访,两组Vm[(8.14±1.25)vs(7.59±1.33)mmol/L]、2 hPG[(10.55±1.49)vs(9.79±1.51)mmol/L]、HbA_1c[(7.74±0.67)%vs(7.42±0.89)%]比较,差异均有统计学意义(P<0.05)。出院6个月后门诊随访,两组FPG[(8.20±1.36)vs(7.79±1.32)mmol/L]、2 hPG[(10.98±1.69)vs(9.95±1.61)mmol/L]和HbA_1c[(7.84±1.02)%vs(7.40±0.95)%]比较,差异仍有统计学意义(P<0.05)。结论患者参与管理模式不仅可在住院期间提高“3C”治疗对血糖控制的效果,且在院外也能改善患者血糖状况。
Objective To verify the effect of patient management on the glycemic control of T2DM patients receiving “3C” treatment. Methods A total of 125 patients with T2DM admitted to Department of Endocrinology, TEDA International Cardiovascular Hospital and “3C” patients were randomly divided into two groups (65 patients in management group and 60 patients in routine mode group). Results At discharge, the patients participated in the management of the model group FPG [(7.69 ± 1.05) vs (7.13 ± 1.13) mmol / L], 2 hPG [(9.85 ± 1.29) vs (9.10 ± 1.11) mmol / L] (1.90 ± 0.35) vs (1.44 ± 0.25), and mean arterial blood glucose fluctuation (MAGE) [(1.36 ± 0.27) vs (1.21 ± 0.21)], respectively. There were statistically significant differences between the two groups Significance (P <0.05). The patients were followed up at 3 months after discharge. The Vm [(8.14 ± 1.25) vs (7.59 ± 1.33) mmol / L], 2 hPG [(10.55 ± 1.49 vs 9.79 ± 1.51) mmol / 7.74 ± 0.67)% vs (7.42 ± 0.89)%], the difference was statistically significant (P <0.05). The patients were followed up at 6 months after discharge. The levels of FPG [(8.20 ± 1.36) vs (7.79 ± 1.32) mmol / L] and 2 hPG [(10.98 ± 1.69) vs (9.95 ± 1.61) mmol / 7.84 ± 1.02)% vs (7.40 ± 0.95)%], the difference was still statistically significant (P <0.05). Conclusion Patient participation in management not only improves the effect of “3C” treatment on blood glucose control during hospitalization, but also improves the blood glucose status of patients in the hospital.